189 related articles for article (PubMed ID: 10632352)
1. Genetic alterations in ERBB2-amplified breast carcinomas.
Isola J; Chu L; DeVries S; Matsumura K; Chew K; Ljung BM; Waldman FM
Clin Cancer Res; 1999 Dec; 5(12):4140-5. PubMed ID: 10632352
[TBL] [Abstract][Full Text] [Related]
2. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
3. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
4. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
5. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification.
Courjal F; Theillet C
Cancer Res; 1997 Oct; 57(19):4368-77. PubMed ID: 9331100
[TBL] [Abstract][Full Text] [Related]
6. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
[TBL] [Abstract][Full Text] [Related]
7. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.
Kauraniemi P; Bärlund M; Monni O; Kallioniemi A
Cancer Res; 2001 Nov; 61(22):8235-40. PubMed ID: 11719455
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.
Andre F; Job B; Dessen P; Tordai A; Michiels S; Liedtke C; Richon C; Yan K; Wang B; Vassal G; Delaloge S; Hortobagyi GN; Symmans WF; Lazar V; Pusztai L
Clin Cancer Res; 2009 Jan; 15(2):441-51. PubMed ID: 19147748
[TBL] [Abstract][Full Text] [Related]
9. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
[TBL] [Abstract][Full Text] [Related]
10. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
Mrhalova M; Kodet R
Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
[TBL] [Abstract][Full Text] [Related]
11. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q.
Orsetti B; Nugoli M; Cervera N; Lasorsa L; Chuchana P; Rougé C; Ursule L; Nguyen C; Bibeau F; Rodriguez C; Theillet C
Br J Cancer; 2006 Nov; 95(10):1439-47. PubMed ID: 17060936
[TBL] [Abstract][Full Text] [Related]
12. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization.
Rennstam K; Ahlstedt-Soini M; Baldetorp B; Bendahl PO; Borg A; Karhu R; Tanner M; Tirkkonen M; Isola J
Cancer Res; 2003 Dec; 63(24):8861-8. PubMed ID: 14695203
[TBL] [Abstract][Full Text] [Related]
13. Molecular cytogenetics of primary breast cancer by CGH.
Tirkkonen M; Tanner M; Karhu R; Kallioniemi A; Isola J; Kallioniemi OP
Genes Chromosomes Cancer; 1998 Mar; 21(3):177-84. PubMed ID: 9523192
[TBL] [Abstract][Full Text] [Related]
14. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization.
Somiari SB; Shriver CD; He J; Parikh K; Jordan R; Hooke J; Hu H; Deyarmin B; Lubert S; Malicki L; Heckman C; Somiari RI
Cancer Genet Cytogenet; 2004 Dec; 155(2):108-18. PubMed ID: 15571796
[TBL] [Abstract][Full Text] [Related]
15. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
16. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
[TBL] [Abstract][Full Text] [Related]
17. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization.
Tong CY; Hui AB; Yin XL; Pang JC; Zhu XL; Poon WS; Ng HK
J Neurosurg; 2004 Feb; 100(2 Suppl Pediatrics):187-93. PubMed ID: 14758948
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
19. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
20. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]